ICCC - ImmuCell Corporation Stock Analysis | Finranks

Stock details

Previous close: 6.52$
Day's range: 6.35 - 6.52$
52-week range: 4.52 - 7.6$
Volume: 9 481
Average volume: 13 510
Beta: -0.45
EPS (TTM): -0.11
PE ratio (TTM): N/A
Market cap: 58 978 946
Shares outstanding: 9 045 851
Dividend yield: N/A
Next earnings date: 2026-05-20
Sector: Healthcare
Industry: Biotechnology

About the company

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defen... read more

CEO: P. F. Te Boekhorst
Country: United States
IPO Date: 1987-04-30
Employees: 84
Fiscal Year End: January - December
Website: https://immucell.com

Revenue Breakdown

Scours / 99.32%

Mastitis / 0.68%

News

No Data

There are no news for this stock.

Chart: ICCC

Loading Chart...

Overall Score

2.3 / 1023%

Financial Strength

Profitability

3.2

Effectiveness

Growth

3.1

Forecast

Valuation

4.8

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	N/A	6.05	1.0
Quick ratio	N/A	5.63	1.0
Debt to Equity	N/A	0.30	1.0
Debt to Assets	N/A	1.04	1.0
Interest coverage	N/A	-16.91	1.0
Weighted average score			1.0

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	19M	17M	26M	28M	28M
Gross Profit	6M	4M	8M	11M	11M
Operating Income	-2M	-6M	-2M	2M	2M
Net Income	-2M	-6M	-2M	-1M	-1M
EBITDA	189K	-3M	1M	4M	4M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	38.16	-11.73	7.0
Operating margin %	-0.76	-24.60	1.0
Net margin %	-37.36	-172.20	1.0
EBITDA margin %	8.55	-201.27	3.0
Cash flow margin %	6.32	-156.39	4.0
Weighted average score			3.2

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	1.54	-57.97	3.0
ROE	2.51	-63.56	3.0
ROIC	1.02	-42.57	3.0
ROCE	1.40	-71.10	3.0
Weighted average score			3.0

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	N/A	N/A	1.0
Next quarter	N/A	N/A	1.0
Current year	N/A	N/A	1.0
Next year	N/A	N/A	1.0
Weighted average score			1.0

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	38.5	-1938.66	N/A	-222.82	3.3
Y/Y	-1.6	-653.19	N/A	-144.1	1.0
3y average	16.7	-5.7	N/A	39.7	5.3
5y average	14.4	-602	N/A	-28.54	2.8
Weighted average score					3.1

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	22.96	-5.25	5.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	1.98	64.66	7.0
P/B	2.03	2.96	6.2
Weighted average score			4.8

DCF Model

DCF Model PeriodN/A

Discount rateN/A

Perpetual growth rateN/A

Revenue 5 year CAGRN/A

FCF 5 year CAGRN/A

Fair value$

Stock price6.52$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$1

UndervaluedStock priceOvervalued

$6.52

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

ImmuCell Corporation (ICCC)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ImmuCell Corporation (ICCC)

Stock details

About the company

Revenue Breakdown

News

Chart: ICCC

Overall Score

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$1

$6.52

Economic Moat

Octagon View

Strength & Weakness